ABVC BioPharma (ABVC) Q1 2026 earnings summary

Executive summary

• Focused on plant-derived drug and device development, with clinical programs in CNS, oncology, and ophthalmology, and a CDMO services subsidiary.

• No revenue recognized in Q1 2026; operations funded by equity, debt, and related party support.

• Strategic land acquisitions in Taiwan to support future R&D and manufacturing.

Financial highlights

• Net loss of $1.69 million for Q1 2026, up 79% year-over-year from $0.94 million in Q1 2025.

• Operating expenses rose 127% to $1.57 million, mainly due to increased stock-based compensation.

• Net cash used in operating activities was $894,243, with a working capital deficit of $4.74 million as of March 31, 2026.

• Cash and cash equivalents at quarter-end were $140,324.

Outlook and guidance

• Management plans to improve liquidity through licensing collections, new financings, cost controls, and debt reduction.

• Ongoing integration of affiliates and expansion of CDMO platform expected to support future cash flows.